Genitourinary Cancers

Latest News

Interim findings from a phase 3 trial support adjuvant pembrolizumab as a new therapeutic option for those with muscle-invasive urothelial carcinoma at high risk of recurrence.
Pembrolizumab Improves DFS Vs Observation in Muscle-Invasive Urothelial Carcinoma

February 8th 2024

Interim findings from a phase 3 trial support adjuvant pembrolizumab as a new therapeutic option for those with muscle-invasive urothelial carcinoma at high risk of recurrence.

Combining pembrolizumab with cabozantinib produces encouraging efficacy in platinum-ineligible patients with advanced urothelial carcinoma, says Rohit K. Jain, MD, MPH.
Pembrolizumab Combo Yields Efficacy in Advanced Urothelial Carcinoma

February 3rd 2024

Benefits with enfortumab vedotin plus pembrolizumab in prespecified patient subgroups with urothelial carcinoma in the EV-302 trial appear to be consistent with outcomes in the overall study population.
Enfortumab Vedotin Combo Improves Outcomes in Urothelial Cancer Subgroups

February 3rd 2024

Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS.
Olaparib Combo Improves Survival Vs Placebo in Metastatic CRPC

January 28th 2024

Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib

January 27th 2024

Video Series
Video Interviews
Podcasts
Lead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.
Latest CME Events & Activities

What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations

View More

Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond

View More

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News